BioCryst falls on wider-than-expected quarterly loss

BioCryst Pharmaceuticals

24/02/2025 14:52

** Drugmaker BioCryst Pharmaceuticals'  BCRX.O  shares fall
11% to $8.20 
    ** Co posts Q4 net loss of 13 cents per share, compared with
analysts' estimates of a loss of 6 cents per share, according to
data compiled by LSEG
    ** Separately in a filing, co discloses it received a notice
from India's Annora Pharma in January regarding Annora's
submission of an application to the FDA seeking approval to
manufacture, use or sell a generic version of BCRX's Orladeyo
before the expiration of patents
    ** The letter alleges that the patents, which expire in
2039, are invalid
    ** Orladeyo is used to prevent attacks of hereditary
angioedema, a rare genetic disorder that causes severe swelling
in the body
    **  BCRX intends to vigorously defend its intellectual
property rights protecting Orladeyo, it said
    ** Co posts Q4 revenue of $131.5 million on strong sales for
Orladeyo, compared with analysts' estimates of $130.2 million 
     ** Expects 2025 total revenue between $560 million and $575
million vs analysts' estimates $545 million
    ** BCRX rose 63% in the last 12 months

 (Reporting by Siddhi Mahatole)
 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))